Five things for pharma marketers to know: Thursday, October 30
Pascal Soriot lays down the law
Sanofi's board reportedly reached out to AstraZeneca CEO Pascal Soriot for its vacant chief executive post, according to unnamed sources from Bloomberg. Chairman Serge Weinberg told reporters yesterday that the company is considering mostly external candidates for the role. The Wall Street Journal wrote Thursday that Viehbacher often made the board of directors feel ill-informed of his plans, and were upset with his “uncommunicative management style.”
Teva CEO Erez Vigodman told analysts on a conference call Thursday that he's optimistic the US Supreme court will rule in its favor on a patent protection suit for multiple sclerosis treatment Copaxone, according to Reuters. The Israeli drugmaker is appealing a judge's 2013 dismissal of a lawsuit brought against Mylan and Sandoz for allegedly infringing on the drug's patents.
AstraZeneca won approval for a two-in-one diabetes pill Thursday, Reuters reported early Thursday morning. The type 2 diabetes treatment will be known as Xigduo XR and is a combination of AZ's SGLT2 Farxiga approved in January 2014, and metformin, making it the first such combination to receive FDA approval.
J&J may have to shell out $250 million to settle 1,000 more lawsuits over its ASR hip claims, an unnamed source tells Bloomberg. J&J settled 8,000 suits earlier this summer doling out an average of about $250,000 per surgery. If the drugmaker can resolve these additional suits, it will have settled about 75% of the total U.S. claims against the hip implant, the news service tell us.
Consumer health product manufacturer Perrigo may reach an agreement soon to acquire Omega Pharma, a Belgian drugmaker specializing in over-the-counter medications. Unnamed sources from Bloomberg said Omega could go for more than $5 billion. Perrigo acquired Elan in July 2013, allowing the company to redomicile in Ireland.